scholarly journals High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children

2019 ◽  
Vol 81 (1) ◽  
pp. 102-109 ◽  
Author(s):  
Sarah F. Benki-Nugent ◽  
Ira Martopullo ◽  
Tony Laboso ◽  
Nancy Tamasha ◽  
Dalton C. Wamalwa ◽  
...  
Blood ◽  
2008 ◽  
Vol 112 (4) ◽  
pp. 1510-1514 ◽  
Author(s):  
Maciej Bogdan Maniecki ◽  
Henrik Hasle ◽  
Lennart Friis-Hansen ◽  
Birgitte Lausen ◽  
Ove Juul Nielsen ◽  
...  

Abstract We describe a novel syndrome of severe toxic symptoms during intravascular hemolysis due to impaired hemoglobin scavenging in 2 children with acute myeloid leukemia undergoing CD33-directed therapy with the immunotoxin gemtuzumab ozogamicin (GO). A simultaneous high plasma hemoglobin, haptoglobin, and low bilirubin after septicemia-induced intravascular hemolysis indicated abrogated clearance of haptoglobin-hemoglobin complexes. This was further supported by low levels of plasma soluble CD163 and a concordant low number of CD163-expressing monocytes. We show that CD163 positive monocytes and macrophages from liver, spleen, and bone marrow coexpress CD33, thus suggesting that the GO-induced cellular cytotoxicity of CD33 positive cells eradicates a significant part of the CD163 positive monocytes and macrophages. The risk of severe toxic symptoms from plasma hemoglobin should be considered after CD33-targeted chemotherapy when the disease is complicated by a pathologic intravascular hemolysis. Furthermore, the cases provide further circumstantial evidence of a key role of (CD163-expressing) monocytes/macrophages in plasma hemoglobin clearance in vivo.


Nutrients ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 2572 ◽  
Author(s):  
Danique van Vliet ◽  
Annemiek M.J. van Wegberg ◽  
Kirsten Ahring ◽  
Miroslaw Bik-Multanowski ◽  
Kari Casas ◽  
...  

Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocognitive outcomes for all patients, as similar plasma phenylalanine concentrations do not seem to have the same consequences to the brain for each PKU individual. To better understand the inter-individual differences in brain vulnerability to high plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are still alive. In total, we identified 16 such cases. While intellectual functioning in these patients was relatively unaffected, they often did present other neurological, psychological, and behavioral problems. Thereby, these “unusual” PKU patients show that the classical symptomatology of untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative importance seems to differ between patients and possibly also with increasing age. Further research should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma phenylalanine concentrations.


2008 ◽  
Author(s):  
Douglas Woods ◽  
John Walkup ◽  
Lawrence D. Scahill ◽  
Alan Peterson ◽  
Sabine Wilhelm ◽  
...  

2019 ◽  
Author(s):  
Rahel Schwotzer ◽  
Markus Gabriel Manz ◽  
Stefanie Pederiva ◽  
Christine Waibel ◽  
Clemens Caspar ◽  
...  

1994 ◽  
Vol 72 (03) ◽  
pp. 434-437 ◽  
Author(s):  
E Bruckert ◽  
A Ankri ◽  
P Glral ◽  
G Turpin

SummaryPlasminogen activator inhibitor type-1 (PAI-1) is a key determinant of the fibrinolytic capacity. Its activity correlates with most of the characteristic features of insulin resistance syndrome, i. e. obesity, high blood pressure and hyperlipidemia.We measured plasma PAI-1 antigen levels in 131 asymptomatic men (aged 44.2 ± 11 years) who had been referred for hyperlipidemia. Those taking medication and those with a secondary hyperlipidemia were excluded.We confirmed the correlation between PAI-1 levels and the following variables: body mass index, blood pressure, triglyceride concentration, and blood glucose and insulin levels before and after an oral glucose tolerance test. We also found a significant and independent correlation between PAI-1 and the concentration of the hepatic enzymes glutamyl transferase, alanine aminotransferase and aspartate aminotransferase.Mild liver abnormalities (presumably steatosis) may thus be one of the factors accounting for high plasma PAI-1 levels in hyperlipidemic patients.


1981 ◽  
Vol 45 (01) ◽  
pp. 051-054 ◽  
Author(s):  
A M Fischer ◽  
J Tapon-Bretaudiere ◽  
A Bros ◽  
F Josso

SummaryIn order to investigate the mechanism of thrombin inactivation in the presence of both antithrombin III (AT III) and α 2-macroglobulin (α 2 M), thrombin and the inhibitors have been purified from human material and thrombin inactivation studied using purified reagents either alone or added to defibrinated plasma. Comparison of clotting and amidolytic activities of residual thrombin allowed to measure the amount of thrombin bound to α 2 M. In a purified reagent system as well as in plasma, part of exogenous thrombin is bound to α 2 M. The amount of bound thrombin is related to α 2 M concentration. Conversely, previous plasma α 2 M depletion by immunoabsorption increases the consumption of heparin-cofactor activity by exogenous thrombin. Thus AT III and α 2 M compete for thrombin inactivation. This finding could be of practical interest in clinical situations associating high plasma α 2 M levels and a decrease of AT III concentration.


1969 ◽  
Vol 21 (02) ◽  
pp. 320-324 ◽  
Author(s):  
K Seiler ◽  
F Duckert

SummaryA case of severe Marcoumar intoxication is described. Eleven hours after the intake a plasma concentration of 15.75 µg/ml was found which corresponds approximately to the 5-fold therapeutic concentration. Repeated administration of vitamin K1 made it possible to avoid extreme lowering of the activity of the clotting factors II, VII and X and to prevent bleeding. Side effects were not observed. The biologic half-life of Phenprocoumon has been found to be shortened at high plasma concentration (3.7 instead of 5.9 days). It is probable that in extreme concentration the drug is less strongly bound to the plasma proteins.


2005 ◽  
Vol 113 (S 1) ◽  
Author(s):  
M Dörr ◽  
U John ◽  
H Wallaschofski ◽  
SB Felix ◽  
H Völzke

1962 ◽  
Vol 41 (4) ◽  
pp. 584-594 ◽  
Author(s):  
Dankwart Reinwein ◽  
Erich Klein

ABSTRACT The iodine metabolism was investigated in 29 patients with euthyroid non-endemic diffuse goiter. 1 to 14 days before thyroidectomy the patients received carrier-free 131I. The chemical iodine fractions (PBI, BEI and iodide) of the thyroid and the labelled iodine compound were analyzed by means of paper- and column chromatography. In one gland the total iodine content varied only by ± 19.6% of the average, the relative shares of PBI, BEI and iodide as well as that of the iodoamino acids being equal. Monoiodotyrosine, diiodotyrosine and thyroxine were found in the thyroid homogenate without hydrolysis. The homogenate after hydrolysis contained more iodotyrosines at the expense of iodothyronines than do normal glands. 17 goiters with normal 131I-uptake showed a high total iodine content (14.2 ± 5.0 mg) whilst 9 goiters with an increased 131I-uptake had low values (3.58 ± 0.6 mg). The opposite was found for the relative shares of BEI with the chromatographically isolated iodothyronines thyroxine, triiodothyronine and an unidentified iodine compound. Goiters with »high plasma PB131I« were characterized by a faster transfer of 131I into the more heavily iodinated compounds than is found in glands with a normal hormonal secretion rate. The highest values for the iodothyronines were found in goiters with increased 131I-uptake together with a high hormonal secretion rate. From this study it appears that the changes in the iodine-poor glands are due to a defective exo- or endogenous iodine supply. The observed alterations in iodine-rich glands are probably induced by a faulty iodine utilization characterized by an incomplete iodotyrosyl-coupling defect.


1973 ◽  
Vol 74 (1) ◽  
pp. 88-104 ◽  
Author(s):  
T. Jolín ◽  
M. J. Tarin ◽  
M. D. Garcia

ABSTRACT Male and female rats of varying ages were placad on a low iodine diet (LID) plus KClO4 or 6-propyl-2-thiouracil (PTU) or on the same diet supplemented with I (control rats). Goitrogenesis was also induced with LID plus PTU in gonadectomized animals of both sexes. The weight of the control and goitrogen treated animals, and the weight and iodine content of their thyroids were determined, as well as the plasma PBI, TSH, insulin and glucose levels. The pituitary GH-like protein content was assessed by disc electrophoresis on polyacrylamide gels. If goitrogenesis was induced in young rats of both sexes starting with rats of the same age, body weight (B.W.) and pituitary growth hormone (GH) content, it was found that both the males and females developed goitres of the same size. On the contrary, when goitrogenesis was induced in adult animals, it was found that male rats, that had larger B.W. and pituitary GH content than age-paired females, developed larger goitres. However, both male and female rats were in a hypothyroid condition of comparable degree as judged by the thyroidal iodine content and the plasma PBI and TSH levels. When all the data on the PTU or KClO4-treated male and female rats of varying age and B.W. were considered together, it was observed that the weights of the thyroids increased proportionally to B.W. However, a difference in the slope of the regression of the thyroid weight over B.W. was found between male and female rats, due to the fact that adult male rats develop larger goitres than female animals. In addition, in the male rats treated with PTU, gonadectomy decreased the B.W., pituitary content of GH-like protein and, concomitantly, the size of the goitre decreased; an opposite effect was induced by ovariectomy on the female animals. However, when goitrogenesis was induced in weight-paired adult rats of both sexes, the male animals still developed larger goitres than the females. Among all the parameters studied here, the only ones which appeared to bear a consistent relationship with the size of the goitres in rats of different sexes, treated with a given goitrogen, were the rate of body growth and the amount of a pituitary GH-like protein found before the onset of the goitrogen treatment. Moreover, though the pituitary content of the GH-like protein decreased as a consequence of goitrogen treatment, it was still somewhat higher in male that in female animals. The present results suggest that GH may somehow be involved in the mechanism by which male and female rats on goitrogens develop goitres of different sizes, despite equally high plasma TSH levels.


Sign in / Sign up

Export Citation Format

Share Document